Information

Back Number of 2025

• NEW
  20 May

  Japan’s first extended-release Rivastigmine transdermal formulation (twice-weekly dosage), “RIVALUEN® LA Patch 25.92 mg / 51.84 mg,” launched and listed in the NHI drug price list

• NEW
  15 May

  Notice of Revisions of Financial Objectives of the 6th Medium-term Business Plan (2024-2026) PROACTIVE Ⅲ

• NEW
  15 May

  FY2024 Supplementary Material of Financial Results

• NEW
  15 May

  Consolidated Financial Results for the Year Ended March 31, 2025(Based on Japanese GAAP)

• NEW
  7 May

  Notice of Revisions of Financial Forecasts

• 1 Apr.

  Updated IR Calendar

• 27 Mar.

  Manufacture and sales approval obtained for Japan's first extended-release Rivastigmine transdermal formulation (twice-weekly dosage), “RIVALUEN® LA Patch 25.92 mg / 51.84 mg”

• 17 Mar.

  Notice of Partial Revision of the Basic Policy for the Development of an Internal Control System

• 17 Feb.

  Acquired approval for manufacturing and marketing generic drugs

• 13 Feb.

  Notice of Revision of Dividend Forecasts for the Fiscal Year Ending March 31, 2025 (69th Fiscal Year)

• 13 Feb.

  FY2024(3rd quarter) Supplementary Material of Financial Results

• 13 Feb.

  Consolidated Financial Results for the Nine Months Ended December 31, 2024(Based on Japanese GAAP)

• 6 Jan.

  Updated IR Calendar

• 6 Jan.

  Integrated Report 2024 has been released